NCT04870606View on ClinicalTrials.gov

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

PHASE3CompletedINTERVENTIONAL
Enrollment

733

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

January 24, 2022

Study Completion Date

April 6, 2022

Conditions
Efficacy and Safety
Interventions
DRUG

Proxalutamide (GT0918)

Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory

DRUG

Placebo

Placebo+Standard of care determined by PI and local regulatory

Trial Locations (8)

29566

Main Street Physician's Care, Little River

29677

WR-Mount Vernon Clinical Research, LLC, Sandy Springs

60618

Olivo Medical and Wellness Center, Chicago

66218

Gtc Research, Shawnee Mission

70006

Platinum Research Network, LLC, Metairie

77024

Lotus Clinical Research, Houston

85051

Absolute Clinical Research, Phoenix

90806

Long Beach Clinical Trials, Long Beach

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT04870606 - Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness | Biotech Hunter | Biotech Hunter